Implementing evidence-based strategies for men with biochemically recurrent and advanced prostate cancer: Consensus recommendations from the US Prostate Cancer Conference 2024

By sjmartinez • December 2, 2024

Bryce AH, Agarwal N, Beltran H, Hussain MH, Sartor O, Shore N, Antonarakis ES, Armstrong AJ, Calais J, Carducci MA, Dorff TB, Efstathiou JA, Gleave M, Gomella LG, Higano C, Hope TA, Iagaru A, Morgans AK, Morris DS, Morris MJ, Petrylak DP, Reiter RE, Rettig MB, Ryan CJ, Sellinger SB, Spratt DE, Srinivas S, Tagawa ST, Taplin ME, Yu EY, Zhang T, McKay RR, Koo PJ, Crawford ED. Implementing evidence-based strategies for men with biochemically recurrent and advanced prostate cancer: Consensus recommendations from the US Prostate Cancer Conference 2024. Cancer. 2024 Dec 1. doi: 10.1002/cncr.35612. Epub ahead of print. PMID: 39616467.

Tags: advanced prostate cancer, androgen receptor pathway inhibitors, Biochemical recurrence, consensus recommendations, Hematology/Oncology, poly(ADP‐ribose) polymerase (PARP) inhibitors, Publications, radioligand therapy, Veterans Administration

RELAY: Final Overall Survival for Erlotinib + Ramucirumab or Placebo in Untreated, EGFR-Mutated Metastatic NSCLC

Nakagawa K, Garon EB, Seto T, Nishio M, Aix SP, Paz-Ares L, Chiu CH, Park K, Novello S, Nadal E, Nishino K, Yoh K, Shih[...]

Relationship Between Perceived COVID-19 Risk and Change in Perceived Breast Cancer Risk: Prospective Observational Study

Baxter-King R, Naeim A, Huang TQ, Sepucha K, Stanton A, Rudkin A, Ryu R, Sabacan L, Vavreck L, Esserman L, Stover Fiscalini A, Wenger NS.[...]

Liquid Biopsy in Hepatocellular Carcinoma: Challenges, Advances, and Clinical Implications

Park J, Lee YT, Agopian VG, Liu JS, Koltsova EK, You S, Zhu Y, Tseng HR, Yang JD. Liquid Biopsy in Hepatocellular Carcinoma: Challenges, Advances,[...]